Ketamine
- Generic Name
- Ketamine
- Brand Names
- Ketalar
- Drug Type
- Small Molecule
- Chemical Formula
- C13H16ClNO
- CAS Number
- 6740-88-1
- Unique Ingredient Identifier
- 690G0D6V8H
- Background
Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic eff...
- Indication
Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior oth...
- Associated Conditions
- -
- Associated Therapies
- General Anesthesia, Induction and Maintenance of General Anesthesia
Ketamine Effects as Preemptive Analgesia
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Universitas Padjadjaran
- Target Recruit Count
- 40
- Registration Number
- NCT06040060
- Locations
- 🇮🇩
Universitas Padjadjaran, Bandung, West Java, Indonesia
Ketamine Treatment Plans for Chronic Conditions
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- RIVER Foundation
- Target Recruit Count
- 500
- Registration Number
- NCT06038409
- Locations
- 🇺🇸
RIVER Telehealth, Helena, Montana, United States
Efficacy of Adding Low Dose Ketamine or Fentanyl to Propofol-dexmedetomidine as Total Intravenous Anesthesia
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Minia University
- Target Recruit Count
- 40
- Registration Number
- NCT06031883
- Locations
- 🇪🇬
Eron, Minya, Egypt
Ketamine-assisted Psychotherapy (KAP) for Patients With Existential Distress Associated With Non-operable GI Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 12
- Registration Number
- NCT06001372
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Three Regimens of Ketamine Infusion in Complex Regional Pain Syndrome
- Conditions
- Interventions
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 75
- Registration Number
- NCT05997134
- Locations
- 🇪🇬
Tanta University, Tanta, El-garbia, Egypt
Evaluation of the Efficacy of Preoperative Ketamine Nebulization on Postoperative Sore Throat Due to Tracheal Intubation for Adult Patients Under General Anesthesia, A Prospective Randomized Controlled Study
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-08-03
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 80
- Registration Number
- NCT05975346
Hemodynamic Effects of Bolus of Ketamine Versus Fentanyl in Patients With Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 86
- Registration Number
- NCT05957302
- Locations
- 🇪🇬
Ahmed Mohamed Hasanin, Cairo, Egypt
Ketamine and Midazolam Infusions for CRPS: Feasibility Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Stanford University
- Registration Number
- NCT05945147
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
- Conditions
- Interventions
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 150
- Registration Number
- NCT05940324
- Locations
- 🇺🇸
Department of Psychiatry & Behavioral Sciences, Stanford, California, United States
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT05915013
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.